How Will Idera (NASDAQ:IDRA) Stock React To New Rating Coverage byH.C. Wainwright?

February 15, 2018 - By Stephen Andrade

 How Will Idera (NASDAQ:IDRA) Stock React To New Rating Coverage byH.C. Wainwright?

Investors sentiment decreased to 1.36 in Q3 2017. Its down 0.10, from 1.46 in 2017Q2. It worsened, as 5 investors sold Idera Pharmaceuticals, Inc. shares while 20 reduced holdings. 11 funds opened positions while 23 raised stakes. 46.97 million shares or 1.60% more from 46.23 million shares in 2017Q2 were reported.

Private Advisor Gp Llc holds 0% or 27,000 shares. Goldman Sachs Gru invested 0% in Idera Pharmaceuticals, Inc. (NASDAQ:IDRA). Gsa Cap Ptnrs Llp holds 256,688 shares. Baker Bros Advsrs L P has 10.31 million shares. Palo Alto Invsts Lc accumulated 616,355 shares or 0.06% of the stock. Broadfin Ltd Liability Corporation reported 2.43M shares stake. Barclays Public Limited Co, United Kingdom-based fund reported 53,786 shares. New York State Common Retirement Fund holds 0% or 78,200 shares. State Of Wisconsin Board has 79,000 shares. Meeder Asset holds 0% of its portfolio in Idera Pharmaceuticals, Inc. (NASDAQ:IDRA) for 381 shares. Schwab Charles Invest Mgmt reported 322,929 shares stake. Tower Limited Liability Co (Trc) reported 12,203 shares stake. Wells Fargo Mn reported 142,423 shares. Manufacturers Life Insurance The accumulated 90,620 shares. Balyasny Asset Mgmt Ltd Co holds 17,916 shares or 0% of its portfolio.

Since October 26, 2017, it had 1 insider buy, and 2 selling transactions for $7.00 million activity. 8.00 million Idera Pharmaceuticals, Inc. (NASDAQ:IDRA) shares with value of $12.00 million were bought by BAKER BROS. ADVISORS LP.

Why Has H.C. Wainwright Given Idera (NASDAQ:IDRA) a $4.0 Price Target

In an analyst report revealed to investors on Thursday morning, analysts at H.C. Wainwright began coverage for Idera (NASDAQ:IDRA) shares. The firm has decided to set a Buy rating along with a $4.0, adding 110.53 % to the target.

Investors sentiment decreased to 1.36 in Q3 2017. Its down 0.10, from 1.46 in 2017Q2. It worsened, as 5 investors sold Idera Pharmaceuticals, Inc. shares while 20 reduced holdings. 11 funds opened positions while 23 raised stakes. 46.97 million shares or 1.60% more from 46.23 million shares in 2017Q2 were reported.

Private Advisor Gp Llc holds 0% or 27,000 shares. Goldman Sachs Gru invested 0% in Idera Pharmaceuticals, Inc. (NASDAQ:IDRA). Gsa Cap Ptnrs Llp holds 256,688 shares. Baker Bros Advsrs L P has 10.31 million shares. Palo Alto Invsts Lc accumulated 616,355 shares or 0.06% of the stock. Broadfin Ltd Liability Corporation reported 2.43M shares stake. Barclays Public Limited Co, United Kingdom-based fund reported 53,786 shares. New York State Common Retirement Fund holds 0% or 78,200 shares. State Of Wisconsin Board has 79,000 shares. Meeder Asset holds 0% of its portfolio in Idera Pharmaceuticals, Inc. (NASDAQ:IDRA) for 381 shares. Schwab Charles Invest Mgmt reported 322,929 shares stake. Tower Limited Liability Co (Trc) reported 12,203 shares stake. Wells Fargo Mn reported 142,423 shares. Manufacturers Life Insurance The accumulated 90,620 shares. Balyasny Asset Mgmt Ltd Co holds 17,916 shares or 0% of its portfolio.

Since October 26, 2017, it had 1 insider buy, and 2 selling transactions for $7.00 million activity. 8.00 million Idera Pharmaceuticals, Inc. (NASDAQ:IDRA) shares with value of $12.00 million were bought by BAKER BROS. ADVISORS LP.

Idera Pharmaceuticals, Inc. (NASDAQ:IDRA) Ratings Coverage

Among 4 analysts covering Idera Pharma (NASDAQ:IDRA), 4 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Idera Pharma has $8 highest and $4.0 lowest target. $5.50’s average target is 189.50% above currents $1.8998 stock price. Idera Pharma had 7 analyst reports since January 6, 2016 according to SRatingsIntel. The firm has “Buy” rating given on Thursday, November 16 by H.C. Wainwright. The stock of Idera Pharmaceuticals, Inc. (NASDAQ:IDRA) earned “Outperform” rating by Wedbush on Wednesday, February 1. The rating was maintained by Piper Jaffray on Thursday, November 9 with “Buy”. Piper Jaffray maintained the shares of IDRA in report on Monday, September 11 with “Buy” rating. Wedbush initiated it with “Outperform” rating and $6.0 target in Wednesday, January 6 report.

The stock decreased 5.01% or $0.1002 during the last trading session, reaching $1.8998. About 965,446 shares traded. Idera Pharmaceuticals, Inc. (NASDAQ:IDRA) has risen 21.13% since February 15, 2017 and is uptrending. It has outperformed by 4.43% the S&P500.

Analysts await Idera Pharmaceuticals, Inc. (NASDAQ:IDRA) to report earnings on March, 21. They expect $-0.08 earnings per share, down 900.00 % or $0.09 from last year’s $0.01 per share. After $-0.10 actual earnings per share reported by Idera Pharmaceuticals, Inc. for the previous quarter, Wall Street now forecasts -20.00 % EPS growth.

Idera Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of oligonucleotide therapeutics for oncology and rare diseases in the United States. The company has market cap of $371.67 million. It uses two drug discovery technology platforms to design and develop drug candidates, including toll-like receptor targeting technology and third-generation antisense technology. It currently has negative earnings. The company's drug candidates include IMO-2125, an agonist that is in Phase I/II clinical trials in combination with ipilimumab and pembrolizumab for the treatment of anti-PD-1 refractory metastatic melanoma and refractory solid tumors; IMO-8400, an antagonist, which is in Phase II clinical trial for the treatment of dermatomyositis.

More important recent Idera Pharmaceuticals, Inc. (NASDAQ:IDRA) news were published by: Prnewswire.com which released: “RM LAW Announces Investigation of Idera Pharmaceuticals, Inc.” on January 30, 2018, also Fool.com published article titled: “Why II-VI, Sanmina, and Idera Pharmaceuticals Slumped Today”, Globenewswire.com published: “BioCryst Pharmaceuticals and Idera Pharmaceuticals Announce Merger to Combine …” on January 22, 2018. More interesting news about Idera Pharmaceuticals, Inc. (NASDAQ:IDRA) was released by: Businesswire.com and their article: “Bragar Eagel & Squire, PC is Investigating the Board of Directors of Idera …” with publication date: January 22, 2018.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.